Skip to content

#罕见病

Today 0 items
Oct 15Thu
  1. biopharmadive.com56

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    The FDA on Oct. 14, 2026 unveiled the "Rare Disease Framework Initiative," a plan to "reimagine" how it regulates rare disease therapies by setting standards for individual conditions rather than a one-size-fits-all approach. The initiative will review policies from preclinical engagement through post-marketing requirements, seek patient and expert input, and, per Bloomberg News, targets initial recommendations for February. The agency will take feedback at an Oct. 28 meeting on its Silver Spring, Maryland campus.

  2. biospace.com62

    FDA's latest rare disease framework seeks to prioritize consistency in flexibility

    The FDA launched its Rare Disease Framework Initiative to standardize how clinical trial requirements are applied across rare diseases while tailoring evidence expectations to what small patient populations can realistically generate. Only 5% of an estimated 10,000 rare conditions affecting 30 million Americans have an FDA-approved treatment. The framework builds on programs such as the Rare Disease Innovation Hub, CDER's ARC program and the RDEA pilot, and follows the November 2025 plausible mechanism pathway. The FDA will hold a meeting on Oct. 28 to gather feedback from patients, advocates and industry.

    Why it matters: FDA policy shift sets consistent rules for rare disease drug development, a core issue for sponsors of gene and cell therapies.

  4. medicalxpress.com53

    Expanded genetic testing and early transplant referrals anchor new myelofibrosis care recommendations

    The American Society of Hematology has issued 10 evidence-based recommendations for managing myelofibrosis, a rare blood cancer affecting up to six per 100,000 people, published in Blood Advances. The guidelines call for extended molecular testing at diagnosis, early transplant consultation for higher-risk patients responding to JAK inhibitors, appropriate JAK inhibitor use by risk level, anemia management strategies, and low-dose aspirin for patients with the JAK2 V617F mutation. Panel chair Brady Stein says the panel hopes the questions posed will set a future research agenda on treatment prediction, anemia and transplant timing.

    Why it matters: First ASH guidelines covering myelofibrosis care decisions from testing to transplant will shape clinical practice in a rare cancer.

  5. doi.org48

    Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety

    Long-term leniolisib was generally well tolerated in 37 patients with activated phosphoinositide 3-kinase delta syndrome treated for a median of 4.3 years. Annual infection rates (P = 0.0005), respiratory infection rates (P = 0.0017) and immunoglobulin replacement therapy use (P = 0.0095) all declined per year of treatment, with clinically meaningful gains in 36-Item Short Form Survey general health scores. This extends the efficacy and safety evidence for leniolisib in APDS well beyond the pivotal trials.

  6. fda.gov53

    FDA Rare Disease Innovation Hub

    The FDA Rare Disease Innovation Hub released its Strategic Agenda on February 2, 2026, setting out its goals and priorities for the coming year for the rare disease community. The Hub, co-led by the directors of CBER, CDER and CDRH with the Oncology Center of Excellence and Office of Orphan Products Development, will focus on products for smaller populations and diseases with variable, poorly understood natural history. It has scheduled public meetings for October 16 and October 28, 2026.

  7. fda.gov51

    FDA Rare Disease Framework Initiative Public Meeting - 10/28/2026

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, from 1:00 p.m. to 5:00 p.m. ET at the FDA White Oak Campus in Silver Spring, Maryland, and via Zoom. The meeting seeks input from patients, advocates, sponsors and others on the FDA's Rare Disease Framework Initiative, which aims to build a fit-for-purpose approach to rare disease drug development in small patient populations. Public remarks will inform the agency's work on the Framework, with input sought on fit-for-purpose review, regulatory predictability, external engagement and CMC considerations.

  8. fda.gov62

    FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

    The FDA launched the Rare Disease Framework Initiative to build a fit-for-purpose framework for developing drugs and biologics for rare diseases, outlined in a new white paper dated October 14, 2026. The initiative, led by the Rare Disease Innovation Hub with the Commissioner's office, CBER and CDER, will tailor regulatory requirements to small patient populations, with only about 5% of rare conditions having an FDA-approved treatment. A public meeting on October 28 at the White Oak campus, facilitated by the Reagan-Udall Foundation, opens a feedback process that will inform new guidance, regulation revisions, training and organizational changes.

  9. fda.gov63

    Rare Disease Framework

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, to gather input on its Rare Disease Framework Initiative, which aims to reimagine the agency's approach to rare disease drug development and review. The framework would tailor regulatory advice and decision-making to the evidence reasonably attainable for each disease, embed the patient voice at defined milestones, leverage external expertise, and apply risk-based approaches to manufacturing review and inspections. Changes could come through regulations, guidance documents and internal processes; FDA set out its aims in a white paper released October 14, 2026.

    Why it matters: FDA's rare disease development and review overhaul could change regulatory expectations for sponsors of orphan drugs.

Oct 14Wed
  1. biospace.com48

    Alnylam bulls and bears fight it out after business-shaking guidance cut

    Alnylam cut full-year guidance by about $200 million after second-quarter sales of the TTR silencer Amvuttra in transthyretin-mediated amyloidosis fell short, and its stock has dropped from near $500 to around $250. Analysts at Guggenheim question whether the ATTR-CM opportunity is smaller than expected or whether stabilizers from Pfizer and BridgeBio are becoming preferred, while TD Cowen reiterated a $482 target and BMO argues the cut reflects second-line patient exhaustion. Alnylam is running Phase 3 trials of nucresiran in ATTR-CM and ATTR-PN, and a Phase 3 cardiovascular outcomes trial of zilebesiran in hypertension.

  2. jamanetwork.com40

    Arginine Treatment and Sickle Cell Disease Pain—A Great STArT, but a Hard End Point

    JAMA commentary discusses arginine as a candidate targeted treatment for sickle cell disease pain crises, which drive more than 70,000 pediatric emergency department visits annually in the US. Current care still relies on intravenous opioids, NSAIDs and fluids, with nearly 30% of discharged patients returning within days and similar readmission rates within 30 days. The piece frames the STArT trial as a starting point toward a treatment addressing vaso-occlusion.

  3. jamanetwork.com73

    From Biological Insight to a New Class of Medicines for Hemophilia A

    The 2026 Lasker-DeBakey Clinical Medical Research Award recognizes researchers who developed a bispecific antibody mimicking blood coagulation factor VIII. The antibody offers a new class of medicines for hemophilia A, a life-threatening bleeding disorder caused by lack of factor VIII. The winners describe how biological insight drove the drug's development.

    Why it matters: Lasker award spotlights a bispecific antibody that created a new treatment class for hemophilia A.

  4. jamanetwork.com77

    The 2026 Albert Lasker Basic Medical Research Award

    Emmanuel Mignot and Masashi Yanagisawa, winners of the 2026 Albert Lasker Basic Medical Research Award, identified the brain peptide orexin and established its role in sleep regulation. Their work linked orexin deficiency to narcolepsy. The Perspective traces how the discovery advanced understanding of the sleep disorder.

    Why it matters: Lasker Award honors the discovery of orexin and its link to narcolepsy.

Oct 13Tue
  1. biorxiv.org49

    Spatially resolved tumor-microenvironment architecture defines therapeutic response in unresectable hepatoblastoma

    Spatially organized tumor-microenvironment architecture distinguishes clinical outcomes in unresectable hepatoblastoma. Spatial transcriptomics (10x Visium, n = 11 tumors) and single-cell spatial imaging (NanoString CosMx, n = 3 tumors) on post-chemotherapy explants identified three architectures: relapse-prone tumors showed centralized, TME-dominated organization with SPP1+ TAMs, CAFs, hypoxia and MDK-LRP1 signaling, while non-relapse tumors showed compartmentalized tumor-immune interactions and preserved epithelial differentiation. Spatial architecture, not composition alone, may explain variable response beyond current risk stratification.

  2. doi.org40

    Treatment adherence and mental health in people with cystic fibrosis and advanced lung disease treated with elexacaftor/tezacaftor/ivacaftor

    Thirty-three people with cystic fibrosis and advanced lung disease maintained moderate-to-high adherence to elexacaftor/tezacaftor/ivacaftor after about 30 months, with overall adherence of 75.6%. At 36 months, sweat chloride had decreased by 57.4 mmol/L, ppFEV1 increased by 19.4%, and BMI increased by 1.6 kg/m2, with improved health-related quality of life across most CFQ-R domains. Concentration difficulties (25.8%) and insomnia (32.3%) persisted and were associated with anxiety.

  3. nature.com80

    FDA nod for rare neurology drug

    The FDA has approved Ionis Pharmaceuticals' Zanvastro (zilganersen), the first disease-modifying drug for Alexander disease, a rare progressive and often fatal neurological condition affecting about one person per 1-3 million. The antisense oligonucleotide targets RNA encoding glial fibrillary acidic protein (GFAP), reducing its overproduction in astrocytes, where excess GFAP forms clumps that disrupt myelination. Patients suffer impaired motor function, seizures, intellectual disability and developmental delays.

    Why it matters: First disease-modifying therapy approved for a rare, previously untreatable neurological condition.

Oct 12Mon
  1. Mult Scler41

    Autologous haematopoietic stem cell transplantation affects paramagnetic rim lesions in multiple sclerosis.

    Autologous haematopoietic stem cell transplantation was associated with a reduction in paramagnetic rim lesions, a marker of chronic inflammation that disease-modifying therapies barely affect. In 30 transplanted people with multiple sclerosis, PRL count decreased in 40% of PRL-positive cases scanned before and after AHSCT and in 57% of those scanned after only, with no new PRL appearing. Annualised PRL disappearance rates were -0.36 and -0.43, suggesting an effect on central nervous system microglia/macrophages.

  2. Sci Adv64

    SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome.

    SMCHD1 represses the entire Prader-Willi syndrome locus in neural lineages in both mice and humans, making it a candidate target for activating the silenced maternal copy of the disease genes. Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus and improved phenotypes in a PWS mouse model. Genome-wide SMCHD1 binding aside, this postearly targeting appeared safe, supporting gene activation therapy for the underlying cause of PWS rather than individual symptoms.

    Why it matters: It identifies a molecular target that activates the silenced maternal allele and improves disease phenotypes in a PWS mouse model.

Oct 11Sun
  1. biorxiv.org68

    Disrupted chromatin architecture blocks B lymphopoiesis in Down syndrome

    Three-dimensional genome architecture organizes human fetal haematopoiesis and explains the B-lineage defect in Down syndrome. Using ChromE-seq, a new single-cell assay jointly profiling chromatin conformation and transcription, the authors built a multimodal atlas of ~400,000 haematopoietic cells from disomic and trisomy 21 fetal liver. Trisomy 21 disproportionately disrupted B-lineage architecture, weakened an EBF1-centred regulatory circuit, and deleting a T21-sensitive EBF1 loop anchor reproduced the CLP-to-B-progenitor bottleneck seen in T21.

    Why it matters: Links 3D chromatin architecture to lineage priming and identifies an EBF1 circuit behind the trisomy 21 B-cell defect.

  2. biorxiv.org70

    A unified framework for quantitative splicing and transcript prediction

    SpliceAI2 is a deep learning model trained end-to-end on splice site, splice junction, and transcript usage data across multiple mammalian species, and it reconstructs complete transcripts directly from genomic sequence. It improves detection and quantification of splice-altering variants across benchmarks covering cryptic splicing, splicing QTLs, and massively parallel reporter assays. In a rare disease cohort, predicted splice-altering variants account for 15% of the excess genetic burden, with about half in deep intronic regions likely missed by exome sequencing.

    Why it matters: SpliceAI2 quantifies splice-altering variant effects genome-wide, including deep intronic variants exome sequencing misses.

Oct 10Sat
  1. thelancet.com71

    [Lecture] 50 years of Ebola research and response

    Peter Piot and Jean-Jacques Muyembe-Tamfum delivered the two Virchow Prize Lectures in October 2026, covering 50 years of Ebola research and response. The lectures, published by The Lancet, trace the history of work on the disease. No further events are scheduled in the material.

    Why it matters: Two leading Ebola researchers reflect on five decades of research and response.

  2. doi.org49

    JAK-inhibitor treatment induces rapid yet incomplete immune reconstitution in STAT1 gain-of-function

    JAK inhibitors produced rapid but incomplete immune reconstitution in two STAT1 gain-of-function patients carrying p.R321S and p.T385M mutations. Changes were seen as early as 1 week after treatment: T cells rebalanced toward a homeostatic status, TCR repertoire diversity increased quickly, and transcriptional dysregulation in monocytes improved, though defects such as natural killer deficiency persisted in one patient. The work defines both the therapeutic reach and the limits of JAK inhibition in STAT1 GOF.

Oct 9Fri
  1. Lancet75

    Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

    A 20 mg oral deucrictibant capsule gave faster onset of symptom relief than placebo in hereditary angioedema attacks, with median relief times of under one and a half hours for deucrictibant and beyond twelve hours for placebo, a statistically significant difference. In the phase 3 RAPIDe-3 crossover trial, 113 participants treated 201 attacks, and no severe, serious or treatment-related discontinuation events occurred. Deucrictibant could become the first orally administered bradykinin B2 receptor antagonist for treating attacks of bradykinin-mediated angioedema.

    Why it matters: Phase 3 data show an oral capsule can relieve hereditary angioedema attacks far faster than placebo.

  2. biocentury.com40

    FDA’s CDER approved nine NMEs in September

    FDA's CDER approved nine new molecular entities in September 2026, its highest monthly total of the year, lifting the year-to-date count to 45, one short of the full-year 2025 figure. Six of the nine approvals were treatments for rare diseases, including first approved therapies for MCT8 deficiency and Alexander disease. Companies behind the approvals include Abbvie, AstraZeneca, Bristol Myers Squibb, Curium Pharma, Egetis Therapeutics, Eisai and Elevar Therapeutics.

  3. thelancet.com52

    [Comment] Deucrictibant: a novel oral on-demand treatment for hereditary angioedema

    A comment in The Lancet discusses deucrictibant, a novel oral on-demand treatment for hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH). The condition causes recurrent, unpredictable angioedema attacks that untreated can last 3–5 days and carry considerable morbidity and mortality, and the swelling does not respond to antihistamines, corticosteroids, or epinephrine. The piece examines an oral on-demand option for this setting.

  4. biospace.com59

    Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARM

    The Alliance for Regenerative Medicine (ARM) has published a playbook, building on FDA draft guidance from this summer, showing how gene-editing developers can reuse toxicity, manufacturing and other data across a platform to cut redundant studies and costs. Beam Therapeutics, which helped create the playbook, designs Phase 1 trials as registrational and aims to move from first-in-human studies to FDA approval in four to five years, versus eight to 10 traditionally. ARM also calls for a bifurcated regulatory framework allowing higher-risk, streamlined development for severe rare diseases with no standard of care, while William Blair analysts say more clarity on the plausible mechanism pathway is needed.

  5. biorxiv.org40

    Coordinated alterations in SWI/SNF chromatin remodeling complex, mRNA splicing and mRNA methylation as hallmarks of salivary gland adenoid cystic carcinoma (SACC)

    Spatial transcriptomics of salivary gland adenoid cystic carcinoma points to coordinated disruption of epigenetic regulation as a contributor to the disease. The SWI/SNF chromatin remodeling complex, the NineTeen Complex, and the m6A RNA methylation complex were shown to interact directly, and immunohistochemistry on 48 tumor samples showed altered abundance of METTL3, METTL14, WTAP, PRP19, CDC5L and PLRG1 proteins. BRM directly regulates genes encoding subunits of these complexes and some EMT marker genes, and re-analysis revealed broad alterations in transcript usage and splicing events.

Oct 8Thu
  1. statnews.com43

    A mother-daughter quest to find fellow members of an ultra-rare genetic community

    A journalist and her nearly 17-year-old daughter Maya, who has Nicolaides-Baraitser syndrome, are tracing the condition and its global community of 337 known patients. The syndrome, first described in a 1993 paper by Paola Nicolaides and Michael Baraitser, has no cure, no medicines and no known disease progression. Their investigation has taken them to Cyprus, England and the United States to meet patients, families and the doctors involved.

  2. Nat Biotechnol66

    Regeneron approval brings relief for 'second skeleton' bone disorder.

    Regeneron has received approval for a treatment for the 'second skeleton' bone disorder, a condition in which bone forms progressively in soft tissue. The approval marks the first regulatory decision for this indication for the company. No dosing, pricing or trial details were disclosed.

    Why it matters: First approval for a Regeneron therapy in a rare progressive bone disorder.

  3. medicalxpress.com61

    NHS labs fail to share data vital for diagnosis and care of rare diseases, investigation finds

    A BMJ investigation finds that three of England's seven NHS Genomics Laboratory Hubs, those covering South East, South West, and North East and Yorkshire, are not routinely submitting genetic variants to public databases such as ClinVar, as required since 2024 under ACGS guidance. Even hubs that submit face significant backlogs. The labs cite staffing, technology and infrastructure gaps and say they plan routine submissions this year, while experts warn rare disease patients are missing out on diagnosis and care.

    Why it matters: Non-sharing of NHS variant data limits rare disease diagnosis and public value of genomic testing.

  4. biopharmadive.com40

    Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

    A Netherlands court blocked sales of Merck's subcutaneous Keytruda Qlex in eight European countries, siding with Halozyme in a patent dispute over its under-the-skin drug delivery technology. Separately, Enliven Therapeutics reached agreement with the FDA on a late-stage trial of relcobitinib in chronic myeloid leukemia, enrolling 450 people to test superiority at spurring a major molecular response. Halozyme is also challenging Merck in a U.S. court after a win in Germany.

    Why it matters: Patent ruling blocks subcutaneous Keytruda across Europe and FDA-aligned CML trial design sharpens competition for Novartis and Merck.

Oct 7Wed
  1. fda.gov40

    Rare Disease Drug Approvals

    FDA's CDER lists recent rare disease drug approvals on its Accelerating Rare Disease Cures Program page. In 2026 alone these include Camzyos for an inherited heart condition in children, Emcitate for MCT8 deficiency, Isembyld for muscle loss in spinal muscular atrophy, and Zanvastro for Alexander Disease, among others. The list spans 2021 to 2026 and links to the underlying FDA news releases.

  2. biorxiv.org47

    Disconnect Between Succinate, Succinyl-CoA, and Histone Succinylation in Cells and Gastrointestinal Stromal Tumors with Succinate Dehydrogenase Deficiency

    Succinate dehydrogenase (SDH) deficiency raises succinyl-CoA in multiple models, but histone succinylation does not increase, and lysine malonylation and glutarylation instead decrease. Liquid chromatography high resolution mass spectrometry across the NCI-60 panel, SDH-deficient and SDH-competent models, and GIST patient tumors showed no correlation between succinate to fumarate ratio and succinyl-CoA, and no rise in succinyl-CoA or desuccinylase expression in bulk tumors. Pharmacological desuccinylase inhibition showed very weak or no selective effect on SDH-deficient cell viability, challenging proposed succinylation-based therapeutic targeting.

  3. biocentury.com41

    RougeTx: Reattaching pericytes to stabilize vessels in HHT

    RougeTx, a Naarden, Netherlands-based spinout of Leiden University Medical Center, launched with a $58 million series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners to advance RTX-001 into the clinic. The oral small molecule, designed for once-daily dosing, aims to stabilize blood vessels by reattaching pericytes rather than suppressing angiogenesis in hereditary hemorrhagic telangiectasia. The company will now move RTX-001 toward clinical testing in HHT.

    Why it matters: Series A funds a first-in-class oral approach to a rare vascular disease with no such option named.

Oct 6Tue
  1. biospace.com48

    FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues

    The FDA has extended its review of Novo's denecimig, an investigational bispecific antibody and next-gen factor VIII mimetic for prophylactic treatment of hemophilia A, citing ongoing facility remediation activities at an unnamed manufacturing site. The agency flagged no efficacy or safety deficiencies, and Novo, which submitted the drug in September 2025 with a decision originally slated for the third quarter, says it is addressing the FDA's requests and still preparing for a 2027 launch in adults and children. The FDA has not shared a new review timeline, and European regulators are also evaluating the programme.

    Why it matters: FDA manufacturing delay affects a potential hemophilia A approval and ties into Novo's broader Catalent-related quality problems.

  2. biospace.com67

    Shionogi makes $2B rare disease play with IntraBio buy

    Shionogi will acquire IntraBio for $2 billion upfront, gaining Aqneursa, the first and only approved treatment for ataxia-telangiectasia and the only therapy for Niemann-Pick disease type C, an ultrarare genetic disorder with around 1,000 potential US patients. Aqneursa generated $68 million in net sales last year in NPC, and Jefferies estimates $1 billion in global peak sales. The deal extends a rare disease build-out that includes Radicava, acquired from Tanabe Pharma for $2.5 billion, and IntraBio continues studying Aqneursa in GM2 gangliosidoses and other disorders.

  3. biocentury.com72

    Building again in rare diseases, Shionogi pays $2B for IntraBio

    Shionogi will acquire privately held IntraBio for $2 billion to expand its rare disease portfolio, gaining rights to Aqneursa levacetylleucine (IB1001), a modified N-acetyl-L-leucine amino acid therapy targeting neurological dysfunction and degeneration. The drug is approved for two indications, including one first-in-disease approval. The deal awaits completion.

    Why it matters: $2 billion rare-disease acquisition adds an approved first-in-disease neurological therapy to Shionogi's portfolio.

  4. fda.gov40

    Rare Disease News & Events

    The FDA's ARC Program reviewed its 2025 rare disease work, reporting more than 30 public speaking engagements, 57-plus workshops, consults or meetings supporting rare disease drug development, and 45,000 rare disease news subscribers served. CDER approved 46 novel drugs in 2025, with 32 approved first in the U.S. and 23 carrying orphan drug designation. In FY25 the Office of Orphan Products Development granted 450 of 657 original orphan-drug designation requests, and public workshops on rare disease data sharing and neonatal product development are scheduled or archived for 2026.

  5. biopharmadive.com65

    Shionogi pays $2B to acquire a rare disease startup

    Shionogi agreed on Oct. 5, 2026 to acquire Texas-based IntraBio for $2 billion in cash, gaining Aqneursa, a marketed treatment for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio, which will become a wholly owned subsidiary of Shionogi's U.S. division, reported $68 million in sales in 2025. Shionogi said it will review the deal's effect on its outlook for the fiscal year ending next March.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org